Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin Target Engagement in Schizophrenia (R21Dose)
NCT02498236Completed
- Sponsor
- University of California, Los Angeles
- Start
- Sep 2015
- Primary completion
- Jul 2017
01
Overview
Randomised, double-blind trial of oxytocin nasal spray in schizophrenia spectrum and other psychotic disorders, sponsored by University of California, Los Angeles. Primary endpoints: Mu Suppression on EEG at 1 week and Pupil Dilation While Observing Faces at 1 week. Started Sep 2015; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
schizophrenia spectrum and other psychotic disorders
Beyond the preview
Go deeper on NCT02498236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02498236.